Share Twitter LinkedIn Facebook Email Douglas G. McNeel, MD of @UWCarbone discusses the phase II trial of a DNA vaccine encoding in patients with nonmetastatic, castration-sensitive prostate cancer. ______ Read here: https://ascopubs.org/doi/abs/10.1200/JCO.19.01701?journalCode=jco&Advertisement
Overview of SYNC-T Technology from Syncromune in Prostate Cancer Treatment – Charles Link, MD Prostate 2 Mins Read
Pioneering Advances in Non-Metastatic Prostate Cancer: Navigating ARPIs and Precision Diagnostics for Tailored Treatment [39 SLIDES] Prostate 5 Mins Read
Promontory Therapeutics: PT-112 triggers organelle stress and ribosomal inhibition Prostate 2 Mins Read